Trial Profile
A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AUS 131 (Primary)
- Indications Advanced breast cancer; Carcinoma; Ductal carcinoma; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 21 Jul 2020 Status changed from active, no longer recruiting to completed.
- 01 Jun 2020 Planned End Date changed from 1 Apr 2020 to 3 Jun 2020.
- 31 May 2020 Primary endpoint has been met. (Proliferation Rate of Triple Negative Breast Cancer)